Helsinki-based Arivin Therapeutics is a biotechnology spin-off company from Aalto University and the University of Helsinki. It is involved in developing therapies to address drug-resistant bacterial infections.
Arivin Therapeutics has raised €3.0M across 1 funding round from 4 investors, most recently a Seed round in Sep 2025. Based in Helsinki, Finland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-09-02 | Seed | €3.0M |
| Angel Investors,Business Finland,Michiel Seerden,private investors |
| View deal → |
